The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The future of the weight loss market might not revolve around GLP-1 drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

Researchers at Massachusetts General Hospital have discovered that meeting the weekly recommended physical activity levels, ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.